# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Edward W. Brooke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML014-SYN
- Date: 2026-01-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Howard Bellamy, MD
- Calendar frame: modern shifted

## Reason for visit

First visit to establish shared care for breast cancer on adjuvant tamoxifen, fourteen weeks after bilateral mastectomy and right axillary dissection. **S**

## Historical basis

- Edward William Brooke III was born in Washington, D.C., on October 26, 1919. **D**
- Brooke was elected attorney general of Massachusetts in 1962 and re-elected in 1964, and in 1966 became the first African American elected to the U.S. Senate by popular vote; he served as a Republican senator from Massachusetts from January 3, 1967, to January 3, 1979. **D**
- In a CNN interview aired on June 11, 2003, Brooke said that in September 2002 he felt discomfort in his right breast, which he dismissed as aging, possible muscle strain, or gas; that he then had a mammogram, a sonogram, and a needle biopsy, which found a malignant tumor; that his breasts had never before been examined by a doctor; and that he had not thought men got breast cancer. **D**
- In the same interview Brooke said he had to be operated on for breast cancer, that the cancer had spread to his lymph nodes, and that all of the lymph nodes on his right side were removed. **D**
- An Associated Press report of June 11, 2003, said that Brooke, 83, had been diagnosed with breast cancer in September, had a double mastectomy, and was free of the cancer, and that he was encouraging men to examine themselves and urging insurers to cover mammograms for men. **D**
- In the 2003 interview Brooke described himself as not a smoker or a drinker and said he exercised and ate fairly good food. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Wants his breast cancer follow-up and tamoxifen managed close to home after his surgery and the start of tamoxifen at another hospital. **S**
- Had not known that men could get breast cancer and dismissed his first symptom as aging or a strained muscle; wants to understand his risk of recurrence and what it means for his family. **S**

## Strengths and supports

- Supports: family and a wide circle of friends and former colleagues **S**

## Medications and allergies

- Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- September 2002: Breast cancer of the right breast in a man, diagnosed after he noticed discomfort in the right breast; mammogram, sonogram, and needle biopsy; he had never had a chest examination by a doctor before **D** (CLM-0003)
- 2002: Operation for breast cancer, reported as a double mastectomy, with removal of the lymph nodes on the right side, to which the cancer had spread **D** (CLM-0004, CLM-0005)

## Procedures and immunizations

- 2025-09-16 to 2025-09-16: Diagnostic mammography of both breasts: 1.9 cm irregular, spiculated retroareolar mass in the right breast (BI-RADS 5); left breast with no mass or gynecomastia (BI-RADS 1) **S**
- 2025-09-16 to 2025-09-16: Ultrasound of both breasts and both axillae: 1.8 cm irregular hypoechoic retroareolar mass in the right breast; one right axillary lymph node with a thickened cortex; left breast and left axilla normal **S**
- 2025-09-18 to 2025-09-18: Ultrasound-guided core needle biopsy of the right breast mass and the right axillary node: invasive ductal carcinoma, grade 2; estrogen receptor 95 percent, progesterone receptor 80 percent, HER2 1+ (negative), Ki-67 15 percent; the node contains metastatic carcinoma **S**
- 2025-10-07 to 2025-10-07: Bilateral mastectomy, at another hospital. Pathology: right breast, invasive ductal carcinoma 1.8 cm, grade 2, margins clear, no lymphovascular invasion; left breast, benign breast tissue **S**
- 2025-10-07 to 2025-10-07: Right axillary lymph node dissection, at the same operation: 1 of 14 lymph nodes with a 4 mm metastasis, no extranodal extension; pT1c pN1a, stage IIA **S**
- 2025-10-14: High-dose influenza vaccine, 2025-2026 season **S**
- 2018-04-10: Tdap vaccine **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

Hemoglobin: 13.8 g/dL; White cell count: 6.1 10*3/uL; Platelets: 214 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.04 mg/dL; eGFR: 71 mL/min/1.73 m²; Calcium: 9.3 mg/dL; ALT: 19 U/L; AST: 23 U/L; Alkaline phosphatase: 76 U/L; Total bilirubin: 0.6 mg/dL; Albumin: 4 g/dL; 25-hydroxyvitamin D: 24 ng/mL (low); PHQ-9: 3. All results are synthetic.

BP 134/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 81.6 kg; BMI 24.4 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, articulate, and courteous; prefers to keep his diagnosis private for now and asks direct questions about his treatment; Mood good; PHQ-9 minimal at the first visit. Functional status: Independent in all activities and instrumental activities of daily living; full shoulder movement on both sides after surgery; Walks 30 to 40 minutes most days. Physical examination is intentionally limited. **S**

## Assessment

1. Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer; status draft. **S**
2. Estrogen receptor-positive status of the breast cancer; status draft. **S**
3. Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review; status draft. **S**
4. Absence of both breasts after bilateral mastectomy; status draft. **S**

## Plan

- Medical oncology consultation to take over adjuvant endocrine therapy, confirm that no further adjuvant treatment is needed, and arrange germline genetic testing. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025) **S**
- Tamoxifen 20 mg daily for an initial five years, with venous thromboembolism symptoms, mood, hot flashes, sexual side effects, adherence, and interacting medicines reviewed at every visit. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Genetic counseling and germline multigene panel testing (including BRCA2, BRCA1, PALB2, CHEK2, and ATM), with a letter for first-degree relatives explaining the result. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024) **S**
- Bone health: DXA at baseline, vitamin D repletion, dietary calcium, and weight-bearing exercise; bone-modifying drugs only for osteoporosis, not to prevent recurrence. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Survivorship surveillance: cancer-related history and examination of both sides of the chest wall and both axillae every 3 to 6 months for 3 years, then every 6 to 12 months to 5 years, then yearly; no routine imaging, blood tests, or tumor markers without symptoms; lymphedema checks. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Distress screening at each visit, at least 150 minutes of activity a week, and a written survivorship care plan. Guideline: Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**

## Guideline basis

- Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020), American Society of Clinical Oncology
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024), American Society of Clinical Oncology and Society of Surgical Oncology
- Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016), American Cancer Society and American Society of Clinical Oncology
- Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge
